Results 221 to 230 of about 146,874 (392)

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer [PDF]

, 2004
Alison Clayton, Sarah Danson, Sanjay Jolly, W. David J. Ryder, P.A. Burt, Alan L. Stewart, P M Wilkinson, Richard Welch, B. Magee, G. Wilson, Anthony Howell, Andrew Wardley   +11 more
openalex   +1 more source

Urothelial carcinoma: Perioperative considerations from top to bottom

CA: A Cancer Journal for Clinicians, EarlyView.
Abstract Urothelial carcinoma is an aggressive entity that is associated with significant morbidity, but there have been major advances in both our understanding of and treatment options for patients with this disease. In this review, the authors focus on novel therapeutic and diagnostic approaches in the perioperative setting, with an emphasis on ...
Wesley Yip, Salvador Jaime‐Casas, Anjaney Kothari, Mary Sullivan, Leslie K. Ballas, Domenique Escobar, Anne K. Schuckman, Jonathan E. Rosenberg, Jonathan A. Coleman   +8 more
wiley   +1 more source

Resistance to HER2-targeted therapy

Research in Molecular Medicine, 2013
Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment.
Reza Valadan, Alireza Rafiei, Mohsen Tehrani, Forough Nejatollahi   +3 more
doaj  

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

New England Journal of Medicine, 2012
J. Baselga, J. Cortés, Sung-Bae Kim, S. Im, R. Hegg, Y. Im, L. Roman, J. Pedrini, T. Pieńkowski, A. Knott, E. Clark, M. Benyunes, G. Ross, S. Swain   +13 more
semanticscholar   +1 more source

A Case of Human Epidermal Growth Factor Receptor 2‐Positive Colon Cancer With Invasive Micropapillary Carcinoma Component

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT A female patient in her 60s tested positive for the fecal occult blood test while undergoing health screening. Colonoscopy revealed a 15‐mm‐sized flat elevated lesion with a central depression in the sigmoid colon. Narrow‐band imaging magnification revealed a Japan Narrow‐Band Imaging Expert Team classification of type 2B, whereas crystal ...
Masashi Kono, Yoriaki Komeda, Hiroshi Kashida, Satoru Hagiwara, Akihiro Yoshida, Shunsuke Omoto, Mamoru Takenaka, Naoko Tsuji, George Tribonias, Masatoshi Kudo   +9 more
wiley   +1 more source

Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer

New England Journal of Medicine, 2017
G. von Minckwitz, M. Procter, E. de Azambuja, D. Zardavas, M. Benyunes, G. Viale, T. Suter, A. Arahmani, N. Rouchet, E. Clark, A. Knott, I. Láng, C. Lévy, D. Yardley, J. Bines, R. Gelber, M. Piccart, J. Baselga   +17 more
semanticscholar   +1 more source

Endoscopic Complete Response to Zolbetuximab for Advanced Gastric Cancer With Claudin 18.2 Positive: A Case Report

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Recently, zolbetuximab combined with chemotherapy has been approved as a first‐line treatment for advanced gastric cancer (GC). However, to date, no endoscopic images demonstrating endoscopic complete response (eCR) to zolbetuximab plus chemotherapy have been reported.
Akinori Sasaki, Tomohiro Yamaba, Ayu Tachibana, Rika Kimura, Gaku Uchiyama, Tsubasa Yoshioka, Risa Okamoto   +6 more
wiley   +1 more source

Cardiotoxicity of Trastuzumab (Herceptin) in Chick Embryos

, 2003
Yuji Yoshiyama, Takashi Sugiyama, Motoko Kanke   +2 more
openalex   +2 more sources

Evaluating Radiotheranostic Targets for Endometrial Cancer. [PDF]

J Nucl Med
Sebastiano J, McGlone SA, Samuels ZV, Grimaldi C, Stoddard A, Galka S, Colaco E, Zeglis BM.   +7 more
europepmc   +1 more source

Patient‐reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials

International Journal of Cancer, Volume 157, Issue 10, Page 2135-2145, 15 November 2025.
What's New? The Quality of Life Questionnaire Core 30 (QLQ‐C30) is useful for assessing patient perspectives on the impact of cancer treatments on quality of life. However, thresholds to determine when patients are experiencing functional or symptomatic burdens remain under explored.
Bradley D. Menz, Natansh D. Modi, Ahmad Y. Abuhelwa, Nicole M. Kuderer, Gary H. Lyman, Sandra M. Swain, Ganessan Kichenadasse, Adel Shahnam, Mark Haseloff, Agnes Vitry, Elke Rammant, Imogen Ramsey, Raymond J. Chan, Ross A. McKinnon, Andrew Rowland, Michael J. Sorich, Ashley M. Hopkins   +16 more
wiley   +1 more source